File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus

TitleA prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus
Authors
Issue Date1996
Citation
Clinical Immunology And Immunopathology, 1996, v. 78 n. 1, p. 41-46 How to Cite?
AbstractIgG anti-endothelial cell antibodies (AECA) were detected in 48.5% of patients with active systemic lupus erythematosus (SLE) and in 7% of patients during remission and were associated with the development of diffuse proliferative lupus nephritis. Sixteen AECA-positive patients were prospectively studied for 25.2 ± 2.9 months. Serial AECA levels correlated with disease activity in 10 (62.5%) patients. Seven (43.8%) of 16 patients remained AECA positive during clinical remission, Among four episodes of disease exacerbation and 16 instances of clinical improvement, 85% (17 episodes) were accompanied by corresponding changes in the level of AECA, while corresponding changes in C3, anti-nuclear antibodies, and anti-double-stranded DNA antibodies were noted in 60, 60, and 80% of cases, respectively (p = not significant). AECA served as the only serologic marker of altered disease activity in five episodes, when C3, ANA, and anti-double-stranded DNA levels remained unaltered. We conclude that the level of AECA can serve as a marker of disease activity in SLE and that serial monitoring of AECA can complement other serologic parameters in the management of patients.
Persistent Identifierhttp://hdl.handle.net/10722/162144
ISSN
1998 Impact Factor: 2.047
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_US
dc.contributor.authorCheng, IKPen_US
dc.date.accessioned2012-09-05T05:17:36Z-
dc.date.available2012-09-05T05:17:36Z-
dc.date.issued1996en_US
dc.identifier.citationClinical Immunology And Immunopathology, 1996, v. 78 n. 1, p. 41-46en_US
dc.identifier.issn0090-1229en_US
dc.identifier.urihttp://hdl.handle.net/10722/162144-
dc.description.abstractIgG anti-endothelial cell antibodies (AECA) were detected in 48.5% of patients with active systemic lupus erythematosus (SLE) and in 7% of patients during remission and were associated with the development of diffuse proliferative lupus nephritis. Sixteen AECA-positive patients were prospectively studied for 25.2 ± 2.9 months. Serial AECA levels correlated with disease activity in 10 (62.5%) patients. Seven (43.8%) of 16 patients remained AECA positive during clinical remission, Among four episodes of disease exacerbation and 16 instances of clinical improvement, 85% (17 episodes) were accompanied by corresponding changes in the level of AECA, while corresponding changes in C3, anti-nuclear antibodies, and anti-double-stranded DNA antibodies were noted in 60, 60, and 80% of cases, respectively (p = not significant). AECA served as the only serologic marker of altered disease activity in five episodes, when C3, ANA, and anti-double-stranded DNA levels remained unaltered. We conclude that the level of AECA can serve as a marker of disease activity in SLE and that serial monitoring of AECA can complement other serologic parameters in the management of patients.en_US
dc.languageengen_US
dc.relation.ispartofClinical Immunology and Immunopathologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntibodies, Antinuclear - Biosynthesis - Blooden_US
dc.subject.meshAutoantibodies - Biosynthesis - Blooden_US
dc.subject.meshCells, Cultureden_US
dc.subject.meshEndothelium, Vascular - Immunologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLupus Erythematosus, Systemic - Blood - Epidemiology - Immunologyen_US
dc.subject.meshMaleen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshSeverity Of Illness Indexen_US
dc.titleA prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosusen_US
dc.typeArticleen_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1006/clin.1996.0006en_US
dc.identifier.pmid8599882-
dc.identifier.scopuseid_2-s2.0-0029921228en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0029921228&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume78en_US
dc.identifier.issue1en_US
dc.identifier.spage41en_US
dc.identifier.epage46en_US
dc.identifier.isiWOS:A1996TW58100006-
dc.identifier.scopusauthoridChan, TM=7402687700en_US
dc.identifier.scopusauthoridCheng, IKP=7102537483en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats